PATENT CLAIM ANALYSIS

Application Number: 16181628
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["424", "001650"]

Abstract:
Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.

Claim (Index 1):
An imaging agent comprising:\n a nanoparticle; a linker; an organic heterocyclic molecule; wherein,\n the imaging agent is capable of labeling light chain (LC) aggregates; and \n the organic heterocyclic molecule has high affinity for amyloid-based aggregates comprising beta-sheet structures.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 98.0
- Lexical Diversity: 1.30435
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13314160', '15026545', '12811049', '15552614', '15258883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6856827053018626
- 35 USC 102 Novelty (BERT): 0.4895604428285758
- Combined Prediction Score: 0.666070479054534
- Mean Citation Score: 167.89954399999996
- Max Citation Score: 173.50372
- Similarity Product: 112.47053640601158

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test